EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieKlinische Studie (Phase II)Open Access

Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma

Paul A Meyers iD, Noah Federman, Najat Daw iD, Peter M Anderson, Lara E Davis iD, AeRang Kim, Margaret E Macy iD, Angela Pietrofeso, Ravin Ratan, Richard F Riedel iD, Matteo Trucco, James B Breitmeyer iD und 2 weitere

Journal of Clinical Oncology · 2024

DOI: 10.1200/jco.24.00020 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Paul A Meyers und 13 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Sarcoma, Ewing, Oncogene Proteins, Fusion. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Ewing Sarcoma (ES), a rare cancer with a pathognomonic translocation resulting in the Ewing sarcoma gene (EWS)::FLI1 oncoprotein, has a poor prognosis in the relapsed/refractory (R/R) setting. Tokalas (TK)216 was designed to bind EWS::FLI1 proteins directly, disrupt protein-protein interactions, and inhibit transcription factor function. TK216 plus vincristine showed synergistic activity in preclinical tumor models. To our knowledge, we report the results of a first-in-class, first-in-human phase I/II trial of TK216 in R/R ES. PATIENTS AND METHODS TK216 was administered intravenously as a continuous infusion to patients with R/R ES in 11 cohorts. The dosing duration of 7 days was later extended to 10, 14, and 28 days. Vincristine could be added on day 1 after cycle 2, per investigators’ choice. The trial used a 3 + 3 design with an expansion cohort at the recommended phase II dose (RP2D). RESULTS A total of 85 patients with a median age of 27 years (range, 11-77) were enrolled. The maximum tolerated dose for the 14-day infusion of TK216, 200 mg/m 2 once daily, was determined in cohort 9 and selected as the RP2D. The median previous number of systemic therapies regimens was three (range, 1-10). The most frequent-related adverse events in patients treated at the RP2D included neutropenia (44.7%), anemia (29.4%), leukopenia (29.4%), febrile neutropenia (15.3%), thrombocytopenia (11.8%), and infections (17.6%). In cohorts 9 and 10, two patients had a complete response, one had a partial response, and 14 had stable disease; the 6-month progression-free survival was 11.9%. There were no responses among the eight patients in cohort 11. CONCLUSION TK216 administered as 14-day continuous infusion with or without vincristine was well tolerated and showed limited activity at the RP2D in R/R ES.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sarcoma, EwingOncogene Proteins, FusionHumansMaleFemaleAdultAdolescentYoung AdultMiddle AgedProto-Oncogene Protein c-fli-1Bone NeoplasmsRNA-Binding Protein EWSChildVincristineAgedInfusions, IntravenousMaximum Tolerated Dose

Substanzen

Oncogene Proteins, FusionProto-Oncogene Protein c-fli-1RNA-Binding Protein EWSEWS-FLI fusion proteinVincristine

Autor:innen und Institutionen

  • Memorial Sloan Kettering Cancer Center, New York, NY.
  • University of California Los Angeles, Los Angeles, CA.
  • The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Cleveland Clinic Children's Hospital, Cleveland, OH.
  • Oregon Health and Science University, Portland, OR.
  • Children's National Hospital, Washington, DC.

ORCID-Profile: Paul A Meyers, Najat Daw, Lara E Davis, Margaret E Macy, Richard F Riedel, James B Breitmeyer, Jeffrey A Toretsky

Förderung

  • NCI NIH HHS

Zitieren

APA

Meyers, P. A., Federman, N., Daw, N., Anderson, P. M., Davis, L. E., Kim, A., Macy, M. E., Pietrofeso, A., Ratan, R., Riedel, R. F., Trucco, M., Breitmeyer, J. B., Toretsky, J. A., & Ludwig, J. A. (2024). Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.24.00020

Vancouver

Meyers PA, Federman N, Daw N, Anderson PM, Davis LE, Kim A, et al. Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma. Journal of Clinical Oncology. 2024. doi:10.1200/jco.24.00020

BibTeX
@article{Meyers2024,
  author = {Meyers, Paul A and Federman, Noah and Daw, Najat and Anderson, Peter M and Davis, Lara E and Kim, AeRang and Macy, Margaret E and Pietrofeso, Angela and Ratan, Ravin and Riedel, Richard F and Trucco, Matteo and Breitmeyer, James B and Toretsky, Jeffrey A and Ludwig, Joseph A},
  title = {Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1200/jco.24.00020}
}
Kostenlos starten →